GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo shows promise for tough cancers
Disease control CompletedThis study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Tailored immunotherapy cocktail shows promise for tough stomach cancer
Disease control CompletedThis phase 2 trial tested personalized immunotherapy combinations for advanced gastric cancer that had worsened after initial chemotherapy. Researchers matched treatments to tumor genetics: patients with certain genetic features received atezolizumab plus ipatasertib, while other…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Targeted drug boosts esophageal cancer treatment in major trial
Disease control CompletedThis phase III trial tested whether adding trastuzumab (Herceptin) to standard chemotherapy and radiation helps people with HER2-positive esophageal cancer. 203 patients were randomly assigned to get chemo and radiation with or without trastuzumab. The study measured how long pat…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New targeted combo shows promise for tough stomach cancer
Disease control CompletedThis phase 3 trial tested whether adding a targeted drug called bemarituzumab to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer that has a specific protein (FGFR2b). The study enrolled 547 adults whose cancer could not be removed by s…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Experimental combo targets Hard-to-Treat GI cancers
Disease control CompletedThis early-phase trial tested two drugs together—pembrolizumab (Keytruda) and XL888—in 47 people with advanced gastrointestinal cancers like colorectal and pancreatic cancer that had spread or could not be removed. The main goal was to find the safest dose and check for side effe…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for stomach cancer: drug cocktail shows promise in early trial
Disease control CompletedThis study tested a mix of three drugs—trastuzumab deruxtecan (a targeted therapy), nivolumab (an immunotherapy), and chemotherapy—in 30 people with untreated HER2-low stomach or gastroesophageal junction cancer. The goal was to first find a safe dose and then see how well it shr…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Center Hospital East • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New cocktail of drugs shows promise for Hard-to-Treat stomach cancers
Disease control CompletedThis early-phase trial tested a combination of two targeted drugs (regorafenib and nivolumab) plus standard chemotherapy in 30 adults with advanced or recurrent stomach, gastroesophageal junction, or esophageal adenocarcinoma that could not be surgically removed. The goal was to …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Center Hospital East • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Immunotherapy combo shows promise against stomach cancer in early trial
Disease control CompletedThis phase 2 trial tested adding the immunotherapy drug durvalumab to a standard chemotherapy regimen (docetaxel, oxaliplatin, S-1) before and after surgery in 68 patients with resectable stomach or gastroesophageal junction cancer. The main goal was to see how many patients had …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can a DNA test predict who will respond to cancer immunotherapy?
Disease control CompletedThis completed Phase 2 trial tested whether a special DNA-based test could predict how well patients with stomach or rectal cancer respond to immunotherapy (tislelizumab) combined with chemotherapy and/or radiation. 189 adults with advanced cancer participated. The goal was to se…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Immunotherapy combo aims to boost stomach cancer survival after surgery
Disease control CompletedThis phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before and after surgery helps people with stomach or gastroesophageal junction cancer. Over 1,000 participants received either pembrolizumab plus chemo or placebo pl…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug combo shows promise for Tough-to-Treat stomach cancer
Disease control CompletedThis phase 2 study tested a combination of two drugs, TAS 102 (Lonsurf) and ramucirumab (Cyramza), in 23 patients with advanced stomach or gastroesophageal junction cancer that had stopped responding to other treatments. The goal was to see if the combo was safe and could help pa…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New cancer drug SGN-B6A tested for safety in chinese patients
Disease control CompletedThis early-stage trial tested the safety of a new drug called SGN-B6A in 6 Chinese patients with advanced solid tumors (lung, head and neck, esophageal, stomach cancers). The main goal was to identify side effects and see how the body processes the drug. It is a first step to see…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug combos aim to boost survival in Hard-to-Treat cancers
Disease control CompletedThis study tested several immunotherapy-based drug combinations in 214 people with advanced stomach, gastroesophageal junction, or esophageal cancer that could not be removed by surgery or had spread. Participants received either standard chemotherapy or chemotherapy plus the imm…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug combo shows promise for tough stomach cancer
Disease control CompletedThis study tested a new treatment combination (GEN-001 plus avelumab) in 42 people with advanced stomach or gastroesophageal junction cancer that had not responded to at least two prior therapies. All participants had a specific marker (PD-L1 positive) on their tumors. The goal w…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Genome & Company • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Immunotherapy boosts standard care for HER2-Positive stomach cancer?
Disease control CompletedThis large Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard trastuzumab plus chemotherapy could improve outcomes for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The study enrolled 738 participants …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug combo shows promise in shrinking stomach tumors before surgery
Disease control CompletedThis study tested a combination of the immunotherapy drug tislelizumab and chemotherapy (XELOX) given before surgery to 28 people with locally advanced stomach or gastroesophageal junction cancer. The goal was to see if this approach could shrink tumors more effectively and be sa…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Immunotherapy combo shows promise in stomach cancer trial
Disease control CompletedThis phase 3 trial tested whether adding an immunotherapy drug called AK104 to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. About 610 participants received either AK104 plus chemo or a placebo plus chemo. The study is c…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New triple therapy shows promise for resistant cancers
Disease control CompletedThis early-phase trial tested a combination of three drugs—afuresertib, sintilimab, and chemotherapy—in 22 adults with solid tumors (including lung, cervical, and stomach cancers) that had stopped responding to prior immunotherapy. The goal was to find a safe dose and see if the …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Bacteria cocktail aims to boost cancer immunotherapy
Disease control CompletedThis study tested a combination of an oral bacterial product (VE800) and the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The goal was to see if the bacteria could help the immune system fight tumors …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Vedanta Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Immunotherapy-Chemo cocktail aims to tame stomach cancer
Disease control CompletedThis Phase 3 trial tested whether adding the immunotherapy drug camrelizumab to standard chemotherapy, followed by camrelizumab plus the targeted drug apatinib, helps people with advanced stomach or gastroesophageal junction cancer live longer. The study enrolled 885 participants…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 18:47 UTC
-
New pill plus immunotherapy shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called TPST-1495, taken as a pill, either alone or combined with the immunotherapy Keytruda (pembrolizumab). The trial included 89 people with advanced solid tumors like colorectal, lung, head and neck, and endometrial cancers wh…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Tempest Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 15:48 UTC
-
Could a plant-based supplement calm chemo-related diarrhea?
Symptom relief CompletedThis phase II trial tested a concentrated plant dietary supplement (made from foods like taro, rice, and carrots) in 30 people with gastrointestinal cancers who had diarrhea from chemotherapy. Participants received the supplement alongside standard anti-diarrheal treatment. The g…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Scientists hunt for biomarkers to personalize stomach cancer treatment
Knowledge-focused CompletedThis study analyzed blood and tumor tissue samples from 28 people with stomach cancer to find biological markers that predict how well immunotherapy (tislelizumab) combined with chemotherapy works before surgery. The goal was to build a model that uses RNA and other factors to fo…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Xijing Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC